. 2022 May 20;19(8):533–550. doi: 10.1038/s41575-022-00608-8

Table 4.

Antiviral combinations recommended by the EASL in DAA-naive patients with compensated liver disease in 2021 if HCV genotype and/or RAS is available

Genotype	Cirrhosis status	Prior treatment	Grazoprevir–elbasvir	Glecaprevir–pibrentasvir	Sofosbuvir–velpatasvir	Sofosbuvir–velpatasvir–voxilaprevir
1b	No cirrhosis	Naive	12 weeks	8 weeks	12 weeks	No
	No cirrhosis	Peg-IFN + RBV
	Compensated cirrhosis	Naive
	Compensated cirrhosis	Peg-IFN + RBV		12 weeks
1a, 2, 4, 5, 6	No cirrhosis	Naive	No^a	8 weeks	12 weeks	No
	No cirrhosis	Peg-IFN + RBV
	Compensated cirrhosis	Naive
	Compensated cirrhosis	Peg-IFN + RBV		12 weeks
3	No cirrhosis	Naive	No	8 weeks	12 weeks	No
	No cirrhosis	Peg-IFN + RBV		12–16 weeks	12 weeks	No
	Compensated cirrhosis	Naive		8 weeks	12 weeks^b	12 weeks
	Compensated cirrhosis	Peg-IFN + RBV		16 weeks	12 weeks^b	12 weeks

Data from ref.⁵. DAA, direct-acting antiviral agent; EASL, European Association for the Study of the Liver; Peg-IFN, pegylated interferon-α. ^a12 weeks of treatment possible in patients infected with hepatitis C virus (HCV) genotype 1 without nonstructural protein 5A (NS5A) resistance-associated substitutions (RASs). ^bIn patients with the Y93H RAS, either addition of ribavirin (RBV) or an alternative regimen is recommended. EASL recommends this approach only in those with cirrhosis.